Open an account

Lyra Therapeutics

LYRA · NASDAQ

$0.19−$0.16 (−45.71%)TodayMarket closed ·
Prev close $0.35

About LYRA

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

Employees
27
Headquarters
Watertown, Massachusetts
Listed
May 1, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
lyratherapeutics.com

LYRA key statistics

Market cap
337.23K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
909
Volume
61
Open price
$0.03
High today
$0.19
Low today
$0.03
52 Week high
$0.88
52 Week low
$0.0004

Lyra Therapeutics (LYRA) at a glance

As of Oct 20, 2026, Lyra Therapeutics (LYRA) shares are priced at $0.19, giving the company a market cap of 337.23K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.03 and $0.19. The current price is 533.3% above the day's low and 0.0% below its high.

Volume so far is 61 shares, below the average of 909 shares a day.

Over the past year Lyra Therapeutics has ranged from $0.0004 to $0.88, and now sits 22% of the way up that range.

Lyra Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY25 it reported -$3.38 per share against an estimate of -$5.36.

LYRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 23.1% on average.

  1. Q4 FY23: reported -$11.00 per share against an estimate of -$16.07
  2. Q1 FY24: reported -$17.50 per share against an estimate of -$13.36
  3. Q2 FY24: reported -$37.00 per share against an estimate of -$16.73
  4. Q3 FY24: reported -$9.00 per share against an estimate of -$11.63
  5. Q4 FY24: reported -$8.00 per share against an estimate of -$6.12
  6. Q1 FY25: reported -$6.00 per share against an estimate of -$6.97
  7. Q2 FY25: reported -$5.51 per share against an estimate of -$6.14
  8. Q3 FY25: reported -$3.38 per share against an estimate of -$5.36

LYRA news

  • Avi Kapoor

    Gold Rises Sharply; Lyra Therapeutics Shares Plunge

  • Avi Kapoor

    US Stocks Lower; Dow Tumbles Over 250 Points

  • Vandana Singh

    Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Rishabh Mishra

    US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&P 500's 'Recovery Is Real' And Not A 'Bull Trap' Or 'Bear Market Rally'

  • Shivdeep Dhaliwal

    Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today

  • Avi Kapoor

    Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May

Similar companies

Companies in the same industry as Lyra Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.